20 June 2013
Keywords: fujisawa, fk838, enters, phase, ii, trials, pharmaceutical
Article | 19 December 1994
Fujisawa Pharmaceutical has begun Phase II trials of its new
antihypertensive diuretic, FK383. The agent, a selective adeonosine (A1)
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 December 1994
12 December 1994
19 June 2013
© 2013 thepharmaletter.com